IN
INNPF.US InnoCan Pharma Corporation
- Market cap
- USD 5.80M
- P/E
- -
- P/B
- 1.21x
- ROE
- -41.9%
- Dividend yield
- -
- Fundamental score
- -
Ratios use the latest price and the current fiscal year annualized from 2 quarters up to Jun 2026.
Is INNPF.US undervalued?
Graham numberThe Graham number of InnoCan Pharma Corporation cannot be estimated reliably (it needs positive earnings and book value).
Graham number = √(22.5 × EPS × book value per share): the most a defensive investor should pay according to Benjamin Graham. An estimate, not a recommendation to buy or sell. How is it calculated?
InnoCan Pharma Corporation fundamental analysis
No fundamental analysis for InnoCan Pharma Corporation yet.
InnoCan Pharma Corporation stock price
Prices on the chart can differ slightly from the closing prices StockSummer uses for its ratios.
About InnoCan Pharma Corporation
InnoCan Pharma Corporation operates as a pharmaceutical technology company in United States, Canada, Europe, and internationally. The company operates through two segments, Online sales and Other Operations. The company develops a cannabidiol (CBD)-loaded liposome drug delivery platform (CBD-LPT), which is in the preclinical trial phase to treat chronic pain management for human and veterinary health sectors. It also offers a pain-relieving topical composition, as well as co…
Full company profileInnoCan Pharma Corporation financial statements
2026 annualized: Fiscal year 2026 is not finished. Income statement and cash flow are annualized from 2 quarters up to Jun 30, 2026, the balance sheet is the latest quarter. Figures change when the annual report is published.
InnoCan Pharma Corporation annual financial statements (USD; K = thousand, M = million, B = billion, T = trillion)
| Item | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 Anlz |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Income Statement | |||||||||||
| Revenue | 643K | 0.00 | 0.00 | 0.00 | 8.00K | 196K | 2.56M | 13.7M | 29.4M | 26.6M | 23.4M |
| Gross Profit | 643K | 0.00 | 0.00 | -23.5K | 3.00K | 121K | 2.11M | 12.0M | 26.2M | 23.9M | 21.3M |
| Operating Income | -131K | -481K | -1.17M | -3.00M | -4.73M | -7.48M | -6.27M | 3.80M | -1.25M | -1.26M | -2.59M |
| EBITDA | - | - | - | -2.98M | -4.93M | -7.37M | -3.70M | -3.77M | -1.21M | 130K | -2.00M |
| Net Income | -604K | -308K | -1.19M | -3.34M | -9.95M | -10.0M | -3.76M | -4.70M | -1.83M | -1.12M | -2.01M |
| EPS | - | - | -0.55 | -1.55 | -4.10 | -2.98 | -1.01 | -1.22 | -0.44 | -0.25 | -0.45 |
| Balance Sheet | |||||||||||
| Total Assets | 1.51M | 1.44M | 660K | 2.58M | 4.33M | 12.6M | 6.98M | 6.94M | 9.26M | 10.5M | 10.4M |
| Total Liabilities | 173K | 385K | 533K | 1.17M | 7.94M | 3.56M | 751K | 2.55M | 2.24M | 2.29M | 2.95M |
| Shareholders' Equity | 1.33M | 1.05M | 127K | 1.41M | -3.61M | 9.01M | 6.23M | 4.39M | 7.02M | 5.60M | 4.80M |
| Cash & Short-term Investments | 453K | 292K | 214K | 1.97M | 2.34M | 11.0M | 4.95M | 3.89M | 5.01M | 6.69M | 6.40M |
| Total Debt | - | - | - | 72.0K | 38.0K | 1.00K | 34.0K | 33.0K | 10.0K | - | - |
| Cash Flow | |||||||||||
| Operating Cash Flow | 238K | -33.1K | -909K | -2.72M | -3.69M | -6.63M | -6.07M | -3.90M | -1.58M | 495K | -1.94M |
| Capital Expenditure | 676.00 | 0.00 | 3.00K | 9.00K | 41.0K | 41.0K | 26.0K | 46.0K | 15.0K | 16.0K | 0.00 |
| Free Cash Flow | - | - | -912K | -2.72M | -3.69M | -6.67M | -6.09M | -3.95M | -1.59M | 479K | -1.96M |
| Ratios | |||||||||||
| ROE | -45.3% | -29.2% | -938.6% | -236.0% | - | -111.5% | -60.5% | -107.2% | -26.1% | -20.1% | -41.9% |
| ROA | -40.1% | -21.4% | -180.6% | -129.2% | -229.6% | -79.9% | -54.0% | -67.7% | -19.8% | -10.7% | -19.4% |
| Net Profit Margin | -94.0% | - | - | - | -124,412.5% | -5,126.0% | -147.1% | -34.4% | -6.2% | -4.2% | -8.6% |
| Debt to Equity | - | - | - | 0.05x | - | 0.00x | 0.01x | 0.01x | 0.00x | - | - |
What these items mean
- Revenue
- Total sales of goods and services in the period.
- Gross Profit
- Revenue minus the direct cost of producing what was sold.
- Operating Income
- Profit from the core business after operating expenses.
- EBITDA
- Earnings before interest, taxes, depreciation and amortization.
- Net Income
- Profit left for shareholders after all expenses, interest and taxes.
- EPS
- Net income divided by shares outstanding.
- Total Assets
- Everything the company owns.
- Total Liabilities
- Everything the company owes.
- Shareholders' Equity
- Assets minus liabilities: the book value that belongs to shareholders.
- Cash & Short-term Investments
- Cash and investments that can be turned into cash quickly.
- Total Debt
- Short and long-term borrowings.
- Operating Cash Flow
- Cash generated by the core business.
- Capital Expenditure
- Cash spent on property, plant and equipment.
- Free Cash Flow
- Operating cash flow minus capital expenditure: cash left for dividends, buybacks or debt repayment.
- ROE
- Return on equity: net income divided by shareholders' equity.
- ROA
- Return on assets: net income divided by total assets.
- Net Profit Margin
- Net income as a share of revenue.
- Debt to Equity
- Total debt divided by shareholders' equity.
InnoCan Pharma Corporation dividends
InnoCan Pharma Corporation has not paid dividends in the last 9 fiscal years.
Last stock split: 1:65 on Sep 5, 2025.
Who owns InnoCan Pharma Corporation
- Insiders 19.26%
- Institutions 0.00%
- Public & others 80.74%
- Shares outstanding 4.50M
- Free float 3.63M
InnoCan Pharma Corporation company profile
- Company name
- InnoCan Pharma Corporation
- Ticker
- INNPF.US
- Exchange
- USA Stocks
- Sector
- Consumer Defensive
- Industry
- Pharmaceuticals
- Fiscal year end
- December
- Address
- 1015, 926 ? 5 Avenue SW, Calgary, AB, Canada, T2P 0N7
- Phone
- 403-777-1519
- Website
- innocanpharma.com
About InnoCan Pharma Corporation
InnoCan Pharma Corporation operates as a pharmaceutical technology company in United States, Canada, Europe, and internationally. The company operates through two segments, Online sales and Other Operations. The company develops a cannabidiol (CBD)-loaded liposome drug delivery platform (CBD-LPT), which is in the preclinical trial phase to treat chronic pain management for human and veterinary health sectors. It also offers a pain-relieving topical composition, as well as compositions for the treatment of hemorrhoid, psoriasis of the scalp, vaginal atrophy, and diabetic symptoms. The company is also involved in development, manufacture, and marketing of cosmetic products. InnoCan Pharma Corporation was founded in 2017 and is headquartered in Calgary, Canada.
InnoCan Pharma Corporation management
5- Ms. Iris BincovichCEO & Interim Chairwoman · born 1969
- Mr. Nelson Harvey Halpern F.C.A., FCPAChief Financial Officer · born 1959
- Mr. Roni KamhiCOO & Director · born 1975
- Mr. Eyal Flom L.L.M., M.B.A.Company Secretary, General Counsel & Independent Director · born 1966
- Dr. Eyal KaloVice President of Research & Development · born 1978